A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.

ABSTRACT:

Background

Inadequate infliximab (IFX) drug exposure remains a clinical challenge and leads to high loss of response rates and therapy failure in inflammatory bowel disease (IBD). We aimed to determine the feasibility and pilot effectiveness of a novel, web-based, mobile IFX dosing calculator (mIDC) for therapy optimization.

Methods

We developed an mIDC leveraging the known clinical variables of C-reative protein (CRP), albumin, patient's weight, disease activity indices, calprotectin, drug trough levels, and antibodies to IFX that significantly affect pharmacokinetics and/or outcomes. A prospective observational cohort study in pediatric and young adult IBD patients receiving maintenance IFX was performed. System-wide practice adoption of mIDC was achieved through a quality

SUBMITTER: Piester T 

PROVIDER: S-EPMC6048868 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature